title: Lipoprotein(a) plasma concentrations, apolipoprotein (a) polymorphism and family history of coronary heart disease in patients with essential hypertension.
abstract: OBJECTIVE
  The purpose of the study was to investigate lipoprotein (a) (Lp(a)) levels and apolipoprotein (a) (apo(a)) phenotypes, and their relationship with a family history of coronary heart disease (CHD) in patients with essential hypertension (EH).
  
  
  METHODS
  One hundred and eight newly diagnosed patients with mild to moderate EH and 159 controls were studied. Lp(a) levels were determined with an ELISA method. Apo(a) isoforms were identified by a capillary immunoblotting technique.
  
  
  RESULTS
  Lp(a) levels and frequency distribution of apo(a) isoforms did not show significant differences between patients and controls. Lp(a) levels in hypertensives with a family history of CHD were significantly higher than in those without a family history of CHD (P < 0.01). Hypertensives with a family history of CHD showed significantly different frequencies of apo(a) isoforms to those without a family history of CHD (P < 0.05). In EH patients with a family history of CHD, apo(a) isoforms of low molecular weight (MW) had a higher prevalence (62.6%), while in hypertensives without a family history of CHD, apo(a) isoforms of high MW were prevalent (81.6%); the difference between the two subgroups was significant (P < 0.001). Multivariate analysis showed that both Lp(a) levels and apo(a) isoforms of low MW are significant variables in distinguishing between the subgroups.
  
  
  CONCLUSIONS
  Lp(a) levels and apo(a) phenotypes do not differ between hypertensives and controls. High Lp(a) levels and apo(a) isoforms of low MW are strongly associated with a family history of CHD in hypertensives. The quantification of Lp(a) levels and the characterization of apo(a) phenotypes may be used for assessment of familial predisposition to CHD in hypertensives.
authors.affiliation: Department of Internal Medicine and Medical Therapeutics, First Medical Clinic, IRCCS Policlinico San Matteo, University of Pavia, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Gazzaruso
authors.forename: P
authors.initials: P
authors.lastname: Buscaglia
authors.forename: A
authors.initials: A
authors.lastname: Garzaniti
authors.forename: G
authors.initials: G
authors.lastname: Bonetti
authors.forename: S
authors.initials: S
authors.lastname: Savino
authors.forename: S
authors.initials: S
authors.lastname: Mariotti
authors.forename: A
authors.initials: A
authors.lastname: Jucci
authors.forename: G
authors.initials: G
authors.lastname: Finardi
authors.forename: D
authors.initials: D
authors.lastname: Geroldi
mesh_terms: D001053:Apolipoproteins / Q000235:genetics*; D053241:Apoprotein(a); D015139:Blotting, Southern; D003327:Coronary Disease / Q000097:blood / Q000150:complications / Q000235:genetics*; D016521:Electrophoresis, Gel, Pulsed-Field; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications*; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009679:Nuclear Family; D010641:Phenotype; D011110:Polymorphism, Genetic / Q000235:genetics*; D012044:Regression Analysis
chemical_list: D001053:Apolipoproteins; D017270:Lipoprotein(a); D053241:Apoprotein(a)